Industry news

What’s the hottest biotech R&D field in venture investing?

John Carroll / ENDPOINTS

If you guessed cancer without even thinking about it, you get a gold Endpoints star. But just how much hotter is oncology compared to every other field in biopharma R&D?

China to pip U.S. researchers to the post on first CRISPR trial

Ben Adams / Fierce Biotech

Initially it looked like a U.S. biotech to be the first; then a team funded by the billionaire co-founder of Napster; now, it looks like it will be Chinese researchers who will start the first-ever human trial using CRISPR gene editing.

The search for a broadly useful HIV cure continues

Anette Breindl / BioWorld

So far, there has been exactly one person who has been cured of AIDS – Berlin patient Timothy Brown. And his treatment, due to both its dangers and its costs, is definitely not suitable for scale-up. 

Experts warn that gains against HIV remarkable, but not irreversible

Anette Breindl / BioWorld

 The 21st International AIDS Conference officially kicked off Monday. But over the weekend, two days of pre-conferences have already addressed a multitude of aspects of the epidemic.

В первом полугодии 2016 года производство медизделий выросло на 13%

Екатерина Макарова / Vademecum

Согласно отчету Росстата, в январе – июне 2016 года отечественные промышленники выпустили медицинской продукции на 15,8 млрд рублей, что на 13,3% больше, чем за аналогичный период 2015 года.

European Pharma and the Unified Patent Court

Leela Barham /BioPharm International

One of the latest efforts to bring greater commonality in the European Union (EU) is the introduction of a European patent supported by a Unified Patent Court (UPC). Naturally the pharmaceutical industry will have a significant interest in improvements to the patent system in Europe; after all patents play an important role in ensuring that returns are made on significant research and development investment. So much so, that some say that protection of intellectual property is at the core of the business.

Biomedicine The White House Is Pushing Precision Medicine, but It Won’t Happen for Years

Mike Orcutt / MIT Technology Review

With the right technologies to collect and make sense of biomedical information, we could speed up the pace of discoveries that lead to a new class of tailor-made drugs. That’s the argument behind the White House’s push for “precision medicine” (see “A Shot in the Arm for Obama’s Precision Medicine Initiative”).

Value-based care necessitates big changes for pharma marketers, says digital pharma agency

Beth Snyder Bulik / FiercePharmaMarketing

Much has been discussed, and some dismissed, when it comes to value-based care in the pharma industry. However, no one can deny that the shift to outcomes-based healthcare is a sea change that will affect big pharma significantly.

Which big biopharma companies put R&D as their top priority?

John Carroll / ENDPOINTS

We love charts at Endpoints. They’re a great way to offer a snapshot of the data that highlight a dramatic comparison for readers. So we were delighted when one of our readers came up with two new charts from last week’s special report on the top 15 R&D budgets in biopharma.

Top R&D innovators in med tech

Emily Wasserman / FierceBiotech

Devicemakers didn’t hold back when it came to R&D in 2015. The industry’s top companies spent a total of $11.670 billion developing new devices and diagnostics last year, an 8% increase from 2014.